Get the Stockscreener App
7.60
0.26%
-0.02
After Hours:
7.57
-0.03
-0.39%
Biocryst Pharmaceuticals Inc stock is traded at $7.60, with a volume of 2.69M.
It is down -0.26% in the last 24 hours and down -12.54% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$7.62
Open:
$7.57
24h Volume:
2.69M
Relative Volume:
1.17
Market Cap:
$1.60B
Revenue:
$331.41M
Net Income/Loss:
$-226.54M
P/E Ratio:
-6.08
EPS:
-1.25
Net Cash Flow:
$-97.31M
1W Performance:
-2.44%
1M Performance:
-12.54%
6M Performance:
+49.61%
1Y Performance:
+7.34%
1-Day Range:
$7.48
$7.885
1-Week Range:
$7.48
$7.885
52-Week Range:
$4.03
$8.88
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Industry
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
BioCryst secures $69 million HHS contract for flu treatment By Investing.com - Investing.com Canada
BioCryst Secures Major US Health Department Influenza Drug Deal - TipRanks
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile - The Manila Times
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile - GlobeNewswire
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile - StockTitan
BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade) (NASDAQ:BCRX) - Seeking Alpha
Wall Street SWOT: BioCryst stock rides Orladeyo wave amid pipeline shifts - Investing.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Holdings Lifted by Cubist Systematic Strategies LLC - MarketBeat
Deerfield Management Company L.P. Series C Boosts Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Deerfield Management Company L.P. Series C Grows Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Avian Flu Treatment Market Research Analysis – Abbott, BioCryst Pharmaceuticals, Cipla, Forrest Pharmaceuticals - Cauverynews
Avoro Capital Advisors LLC Sells 480,000 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Influenza Vaccines Market Future Business Opportunities - openPR
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by XTX Topco Ltd - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by Seven Eight Capital LP - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
BioCryst Pharmaceuticals Insiders Placed Bullish Bets Worth US$1.05m - Simply Wall St
Orladeyo may soon be available through Canada’s healthcare system - Angioedema News Today
Plasma Protease C1-inhibitor Market Poised for Rapid - openPR
BioCryst finalizes Canadian deal for HAE drug PrORLADEYO By Investing.com - Investing.com Canada
BioCryst finalizes Canadian deal for HAE drug PrORLADEYO - Investing.com India
BioCryst finalizes Canadian deal for HAE drug PrORLADEYO By Investing.com - Investing.com Australia
BioCryst finalizes Canadian deal for HAE drug PrORLADEYO - Investing.com
BioCryst finalizes Canadian deal for HAE drug PrORLADEYO By Investing.com - Investing.com UK
BioCryst and the pan-Canadian Pharmaceutical Alliance - GlobeNewswire
BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks - GlobeNewswire Inc.
TD Asset Management Inc Acquires New Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Bank of New York Mellon Corp Has $4.80 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BCRXBioCryst Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals - GuruFocus.com
BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals - Yahoo Finance
Rice Hall James & Associates LLC Sells 71,904 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium - StockTitan
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium - GlobeNewswire
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium - The Bakersfield Californian
BioCryst appoints new chief medical officer to lead research - Investing.com India
BioCryst appoints new chief medical officer to lead research - Investing.com
BioCryst Appoints Dr. Donald Fong Chief Medical Officer - GlobeNewswire
BioCryst Appoints Dr. Donald Fong Chief Medical Officer - StockTitan
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
BioCryst stock touches 52-week high at $8.88 amid growth By Investing.com - Investing.com Canada
BioCryst stock touches 52-week high at $8.88 amid growth - Investing.com
BioCryst stock touches 52-week high at $8.88 amid growth By Investing.com - Investing.com UK
BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 1-Year High at $8.75 - MarketBeat
Hereditary Angioedema Therapeutics Market Size Report, 2032 - Global Market Insights
(BCRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
High Growth Tech Stocks To Watch In August 2024 - Simply Wall St
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 3% - MarketBeat
BCRX: 3 High-Potential Biotech Stocks Under $10 - StockNews.com
Avian influenza Treatment Market Booming Worldwide With - openPR
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):